Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $506.59, for a total value of $4,812,605.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $164,359,579.37. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $529.14 on Thursday. The stock has a market capitalization of $22.69 billion, a P/E ratio of 18.93, a P/E/G ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The stock’s 50-day simple moving average is $534.23 and its 200 day simple moving average is $537.17.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the business earned $6.41 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Torren Management LLC purchased a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Toth Financial Advisory Corp grew its position in United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 48 shares during the period. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. Fiduciary Financial Advisors purchased a new position in United Therapeutics during the second quarter valued at $30,000. Finally, WealthCollab LLC boosted its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.